We are in the early days of a revolution in cancer medicine. One that takes us from the broad-based approach of chemotherapy to the selective targeting of cells informed by the genetics of individual tumors. To use the war analogy, we are moving from the indiscriminate use of large-scale carpet-bombing to the pinpoint accuracy of guided missile attacks.